Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer

Conclusions
DA treatment did not impact EFS or OS in routine adjuvant BC treatment.

Source: Annals of Oncology - December 19, 2013 Category: Cancer & Oncology Authors: Nitz, U., Gluz, O., Zuna, I., Oberhoff, C., Reimer, T., Schumacher, C., Hackmann, J., Warm, M., Uleer, C., Runde, V., Dunnebacke, J., Belzl, N., Augustin, D., Kates, R. E., Harbeck, N., on behalf of the West German Study Group Tags: original articles Source Type: research